| 29 Jan, 2011 - 2:41 pm |
I hear some interesting new developments may be on the horizon with regard to CGRP receptor antagonists soon being made available in treating and managing CH conditions.
From my limited and uneducated understanding - they offer the possibility of a preventive drug prohibiting vasodilation taken daily, without the rebound headache effects associated with abortive triptans. I may be wrong - I have limited knowledge in this area (I am not a specialist...)
I am not aware that they are past clinical trial stage or availiable/approved for use in Australia yet.
Let's hope they work, are approved for use and that they get put on the PBS!
Has anyone out there been given access to a CGRP receptor antagonist yet?
If so, would anyone like to share their thoughts/experiences on the subject?
Some basic info: http://en.wikipedia.org/wiki/Calcitonin_gene-related_peptide
Cheers, Ben.This post was edited on 29/01/2011 at 2:49 pm
| 0 people like this |
there has been a great deal of both excitement and concern in relation to what this means for CH sufferers. As far as I can tell from the research I've done, when these meds do actually become available to us (which will not be for at least 5 years) they will have a great impact on all sufferers. No more vaso-constrictive side effects such as chest pain, heart issues, Raynaurd's and no more amputations! I just wish we had these options earlier. 